Diabetes Patients Set to Benefit From Heart Disease Data Investment
People living with diabetes could be set to benefit from a major research initiative to untangle the link between diabetes and heart disease – two of the most pressing global health crises.
The project – led by our Data Science Centre – will allow researchers from across the UK to safely access health data. This will speed up the search for better prevention and treatment of diabetes.
More than 4.9 million people in the UK are living with diabetes, and 90% of those have type 2 diabetes. Cardiovascular diseases – such as heart attack and stroke – are among the leading causes of death in people with diabetes, who are up to three times more likely to develop a heart condition than the general population. Diabetes damages blood vessels, making them easier to become clogged or blocked.
We are partnering with Diabetes UK and Health Data Research UK to launch a new initiative, named the Diabetes Data Science Catalyst. We aim to discover ways of lowering the rates of type 2 diabetes and improving care for those with all types of diabetes, and in doing so, reduce the risk of heart disease.
The Catalyst will enable researchers to securely and ethically access and link the UK’s unique ‘big data’ that is distributed across registries, hospital records and GP datasets. Information that could identify patients, such as names and addresses, are taken out before researchers access the data.
The Catalyst builds on our £10 million investment in the BHF Data Science Centre to promote the safe and ethical use of health data for research into the causes, prevention, and treatment of heart and circulatory diseases.
Professor Ewan Pearson, Associate Director of the BHF Data Science Centre, who will lead the Catalyst, says:
“It’s shocking that 590 heart attacks and 770 strokes are caused by diabetes in the UK every week. This collaboration will allow a deeper understanding of the causes and progression of diabetes as a major cardiovascular risk factor, and, most importantly, drive improvements in patient care to save lives.”
Professor Sir Nilesh Samani, our Medical Director, said:
“At the BHF, we recognise the tremendous potential of data science as we enter a new age of digital medicine. That’s why we are delighted to be working with Diabetes UK and Health Data Research UK to launch the Diabetes Data Science Catalyst. The BHF and Diabetes UK share a common goal to reduce the burden of cardiovascular diseases in people living with with diabetes and this new initiative will strengthen our ability to tackle this important problem.”
“By unlocking the power of data, we will be able to better understand how diabetes increases the risk of developing deadly heart and circulatory conditions, and how we can save families from this heartbreak.”
Dr Elizabeth Robertson, Director of Research at Diabetes UK, said:
“We’re delighted to be partnering with Health Data Research UK and the BHF Data Science Centre to launch the Diabetes Data Science Catalyst.
“The Diabetes Data Science Catalyst has the potential to enable data-driven research, yielding insights that will improve healthcare and move us closer to a future when cardiovascular disease is no longer among the leading causes of death in people with diabetes. By involving people with diabetes in this cutting-edge research, we’re confident that any changes in diabetes care resulting from this initiative will better support the needs of people living day-to-day with this relentless condition.”
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more